Last 12 months
Inside the activity.
0 purchase rows · 16 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 7 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2022 Filed Aug 3, 2022 17:29 UTC |
WHITE ROBERT JOHNEVP & Pres. Medical Surgical
|
GrantPerformance Share Units · Derivative | 21,487 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020408 · form4.xml · derivative · entry 3 WHITE ROBERT JOHN · CIK 0001726709 · EVP & Pres. Medical Surgical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,487 Underlying: Performance Share Units · 21,487 shares Expires not disclosed F3 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F4 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 21,487 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F5 · derivative.exercise_date: Vests on August 1, 2025. F5 · derivative.expiration_date: Vests on August 1, 2025. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 17:29 UTC |
WHITE ROBERT JOHNEVP & Pres. Medical Surgical
|
GrantOrdinary Shares | 8,595 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020408 · form4.xml · nonDerivative · entry 1 WHITE ROBERT JOHN · CIK 0001726709 · EVP & Pres. Medical Surgical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,351 F1 · shares: The restrictions on the award shall lapse 100% on the third anniversary of the Grant Date. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 17:34 UTC |
Surface Carol AEVP, Chief HR Officer
|
GrantStock Option (Right to Buy) · Derivative | 40,754 | $0.00 Strike: $93.08 | $0.00 |
DisclosureSEC source: 0001127602-22-020412 · form4.xml · derivative · entry 4 Surface Carol A · CIK 0001485966 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,754 Underlying: Ordinary Shares · 40,754 shares Expires 2032-08-01 F5 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 17:34 UTC |
Surface Carol AEVP, Chief HR Officer
|
GrantPerformance Share Units · Derivative | 12,893 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020412 · form4.xml · derivative · entry 3 Surface Carol A · CIK 0001485966 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,893 Underlying: Performance Share Units · 12,893 shares Expires not disclosed F2 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F3 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 12,893 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F4 · derivative.exercise_date: Vests on August 1, 2025. F4 · derivative.expiration_date: Vests on August 1, 2025. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 17:34 UTC |
Surface Carol AEVP, Chief HR Officer
|
GrantOrdinary Shares | 5,157 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020412 · form4.xml · nonDerivative · entry 1 Surface Carol A · CIK 0001485966 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,193 F1 · shares: The restrictions on the award shall lapse 100% on the third anniversary of the Grant Date. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:50 UTC |
Wall Brett A.EVP & Pres Neuroscience
|
GrantStock Option (Right to Buy) · Derivative | 59,433 | $0.00 Strike: $93.08 | $0.00 |
DisclosureSEC source: 0001127602-22-020428 · form4.xml · derivative · entry 3 Wall Brett A. · CIK 0001473812 · EVP & Pres Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,433 Underlying: Ordinary Shares · 59,433 shares Expires 2032-08-01 F5 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:50 UTC |
Wall Brett A.EVP & Pres Neuroscience
|
GrantPerformance Share Units · Derivative | 18,802 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020428 · form4.xml · derivative · entry 2 Wall Brett A. · CIK 0001473812 · EVP & Pres Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,802 Underlying: Performance Share Units · 18,802 shares Expires not disclosed F2 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F3 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 18,802 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F4 · derivative.exercise_date: Vests on August 1, 2025. F4 · derivative.expiration_date: Vests on August 1, 2025. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:50 UTC |
Wall Brett A.EVP & Pres Neuroscience
|
GrantOrdinary Shares | 7,521 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020428 · form4.xml · nonDerivative · entry 1 Wall Brett A. · CIK 0001473812 · EVP & Pres Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,646 F1 · shares: The restrictions on the award shall lapse 100% on the third anniversary of the Grant Date. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 17:32 UTC |
Fong Ivan KEVP GENERAL COUNSEL & SECR
|
GrantStock Option (Right to Buy) · Derivative | 54,849 | $0.00 Strike: $93.08 | $0.00 |
DisclosureSEC source: 0001127602-22-020410 · form4.xml · derivative · entry 3 Fong Ivan K · CIK 0001342238 · EVP GENERAL COUNSEL & SECR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,849 Underlying: Ordinary Shares · 54,849 shares Expires 2032-08-01 F6 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 17:32 UTC |
Fong Ivan KEVP GENERAL COUNSEL & SECR
|
GrantPerformance Share Units · Derivative | 17,351 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020410 · form4.xml · derivative · entry 2 Fong Ivan K · CIK 0001342238 · EVP GENERAL COUNSEL & SECR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,351 Underlying: Performance Share Units · 17,351 shares Expires not disclosed F3 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F4 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 17,351 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F5 · derivative.exercise_date: Vests on August 1, 2025. F5 · derivative.expiration_date: Vests on August 1, 2025. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 17:32 UTC |
Fong Ivan KEVP GENERAL COUNSEL & SECR
|
GrantOrdinary Shares | 6,941 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020410 · form4.xml · nonDerivative · entry 1 Fong Ivan K · CIK 0001342238 · EVP GENERAL COUNSEL & SECR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,722 F1 · shares: The restrictions on the award shall lapse 100% on the third anniversary of the Grant Date. F2 · balance_after: This balance increased by 410 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:24 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 84,905 | $0.00 Strike: $93.08 | $0.00 |
DisclosureSEC source: 0001127602-22-020404 · form4.xml · derivative · entry 7 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,905 Underlying: Ordinary Shares · 84,905 shares Expires 2032-08-01 F6 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:24 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GrantPerformance Share Units · Derivative | 26,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020404 · form4.xml · derivative · entry 6 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,859 Underlying: Performance Share Units · 26,859 shares Expires not disclosed F3 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F4 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 26,859 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F5 · derivative.exercise_date: Vests on August 1, 2025. F5 · derivative.expiration_date: Vests on August 1, 2025. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:24 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GrantOrdinary Shares | 10,744 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020404 · form4.xml · nonDerivative · entry 1 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,962 F1 · shares: The restrictions on the award shall lapse 100% on the third anniversary of the Grant Date. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:53 UTC |
Smith Gregory LEVP Global Ops & Supply Chain
|
GrantStock Option (Right to Buy) · Derivative | 44,151 | $0.00 Strike: $93.08 | $0.00 |
DisclosureSEC source: 0001127602-22-020430 · form4.xml · derivative · entry 3 Smith Gregory L · CIK 0001533098 · EVP Global Ops & Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,151 Underlying: Ordinary Shares · 44,151 shares Expires 2032-08-01 F6 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:53 UTC |
Smith Gregory LEVP Global Ops & Supply Chain
|
GrantPerformance Share Units · Derivative | 13,967 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020430 · form4.xml · derivative · entry 2 Smith Gregory L · CIK 0001533098 · EVP Global Ops & Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,967 Underlying: Performance Share Units · 13,967 shares Expires not disclosed F3 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F4 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 13,967 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F5 · derivative.exercise_date: Vests on August 1, 2025. F5 · derivative.expiration_date: Vests on August 1, 2025. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:53 UTC |
Smith Gregory LEVP Global Ops & Supply Chain
|
GrantOrdinary Shares | 5,587 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020430 · form4.xml · nonDerivative · entry 1 Smith Gregory L · CIK 0001533098 · EVP Global Ops & Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,783 F1 · shares: The restrictions on the award shall lapse 100% on the third anniversary of the Grant Date. F2 · balance_after: This balance increased by 291 shares due to exempt transactions such as dividend reinvestment and employee stock purchase plan. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:22 UTC |
Martha GeoffreyDirector · Chairman and CEO
|
GrantStock Option (Right to Buy) · Derivative | 224,996 | $0.00 Strike: $93.08 | $0.00 |
DisclosureSEC source: 0001127602-22-020402 · form4.xml · derivative · entry 3 Martha Geoffrey · CIK 0001560409 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,996 Underlying: Ordinary Shares · 224,996 shares Expires 2032-08-01 F5 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:22 UTC |
Martha GeoffreyDirector · Chairman and CEO
|
GrantPerformance Share Units · Derivative | 71,176 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020402 · form4.xml · derivative · entry 2 Martha Geoffrey · CIK 0001560409 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,176 Underlying: Performance Share Units · 71,176 shares Expires not disclosed F2 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F3 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 71,176 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F4 · derivative.exercise_date: Vests on August 1, 2025. F4 · derivative.expiration_date: Vests on August 1, 2025. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:22 UTC |
Martha GeoffreyDirector · Chairman and CEO
|
GrantOrdinary Shares | 28,471 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020402 · form4.xml · nonDerivative · entry 1 Martha Geoffrey · CIK 0001560409 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,497 F1 · shares: The restrictions on the award shall lapse 100% on the third anniversary of the Grant Date. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 17:45 UTC |
TEN HOEDT ROBEVP & President EMEA
|
GrantStock Option (Right to Buy) · Derivative | 57,735 | $0.00 Strike: $93.08 | $0.00 |
DisclosureSEC source: 0001127602-22-020421 · form4.xml · derivative · entry 3 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,735 Underlying: Ordinary Shares · 57,735 shares Expires 2032-08-01 F5 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 17:45 UTC |
TEN HOEDT ROBEVP & President EMEA
|
GrantPerformance Share Units · Derivative | 18,264 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020421 · form4.xml · derivative · entry 2 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,264 Underlying: Performance Share Units · 18,264 shares Expires not disclosed F2 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F3 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 18,264 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F4 · derivative.exercise_date: Vests on August 1, 2025. F4 · derivative.expiration_date: Vests on August 1, 2025. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 17:45 UTC |
TEN HOEDT ROBEVP & President EMEA
|
GrantOrdinary Shares | 7,306 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020421 · form4.xml · nonDerivative · entry 1 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,483 F1 · shares: The restrictions on the award shall lapse 100% on the third anniversary of the Grant Date. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:41 UTC |
Salmon SeanEVP & President Cardiovascular
|
GrantStock Option (Right to Buy) · Derivative | 67,924 | $0.00 Strike: $93.08 | $0.00 |
DisclosureSEC source: 0001127602-22-020417 · form4.xml · derivative · entry 3 Salmon Sean · CIK 0001792380 · EVP & President Cardiovascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,924 Underlying: Ordinary Shares · 67,924 shares Expires 2032-08-01 F5 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:41 UTC |
Salmon SeanEVP & President Cardiovascular
|
GrantPerformance Share Units · Derivative | 21,487 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020417 · form4.xml · derivative · entry 2 Salmon Sean · CIK 0001792380 · EVP & President Cardiovascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,487 Underlying: Performance Share Units · 21,487 shares Expires not disclosed F2 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F3 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 21,487 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F4 · derivative.exercise_date: Vests on August 1, 2025. F4 · derivative.expiration_date: Vests on August 1, 2025. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:41 UTC |
Salmon SeanEVP & President Cardiovascular
|
GrantOrdinary Shares | 8,595 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020417 · form4.xml · nonDerivative · entry 1 Salmon Sean · CIK 0001792380 · EVP & President Cardiovascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,214 F1 · shares: The restrictions on the award shall lapse 100% on the third anniversary of the Grant Date. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:38 UTC |
Kirk Jennifer MChief Accounting Officer
|
GrantStock Option (Right to Buy) · Derivative | 1,416 | $0.00 Strike: $93.08 | $0.00 |
DisclosureSEC source: 0001127602-22-020414 · form4.xml · derivative · entry 4 Kirk Jennifer M · CIK 0001613343 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,416 Underlying: Ordinary Shares · 1,416 shares Expires 2032-08-01 F6 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:38 UTC |
Kirk Jennifer MChief Accounting Officer
|
GrantStock Option (Right to Buy) · Derivative | 18,679 | $0.00 Strike: $93.08 | $0.00 |
DisclosureSEC source: 0001127602-22-020414 · form4.xml · derivative · entry 3 Kirk Jennifer M · CIK 0001613343 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,679 Underlying: Ordinary Shares · 18,679 shares Expires 2032-08-01 F6 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:38 UTC |
Kirk Jennifer MChief Accounting Officer
|
GrantPerformance Share Units · Derivative | 5,909 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020414 · form4.xml · derivative · entry 2 Kirk Jennifer M · CIK 0001613343 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,909 Underlying: Performance Share Units · 5,909 shares Expires not disclosed F3 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F4 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 5,909 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F5 · derivative.exercise_date: Vests on August 1, 2025. F5 · derivative.expiration_date: Vests on August 1, 2025. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:38 UTC |
Kirk Jennifer MChief Accounting Officer
|
GrantOrdinary Shares | 2,364 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020414 · form4.xml · nonDerivative · entry 1 Kirk Jennifer M · CIK 0001613343 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,630 F1 · shares: The restrictions on the award shall lapse 100% on the third anniversary of the Grant Date. F2 · balance_after: This balance increased by 332 shares due to exempt transactions such as dividend reinvestment and employee stock purchase plan. Read SEC document |
| July 29, 2022 Filed Aug 2, 2022 17:44 UTC |
Liddicoat John REVP & President of Americas
|
Disposition to issuerOrdinary Shares | 6,543 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020222 · form4.xml · nonDerivative · entry 1 Liddicoat John R · CIK 0001752060 · EVP & President of Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,374 F1 · shares: Represents shares of performance-vesting restricted stock granted in July 2019 and earned dividend equivalent units that have been forfeited based on the Company's failure to meet the cumulative three year non-GAAP diluted earnings per share ("EPS") growth performance target. F2 · balance_after: This balance increased by 795 shares due to exempt acquisitions through dividend reinvestment and our employee stock purchase plan. Read SEC document |
| July 29, 2022 Filed Aug 2, 2022 17:26 UTC |
WHITE ROBERT JOHNEVP & Pres. Medical Surgical
|
Disposition to issuerOrdinary Shares | 12,397 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020201 · form4.xml · nonDerivative · entry 1 WHITE ROBERT JOHN · CIK 0001726709 · EVP & Pres. Medical Surgical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,756 F1 · shares: Represents shares of performance-vesting restricted stock granted in July 2019 and earned dividend equivalent units that have been forfeited based on the Company's failure to meet the cumulative three year non-GAAP diluted earnings per share ("EPS") growth performance target. F2 · balance_after: This balance increased by 723 shares due to exempt acquisitions through dividend reinvestment and our employee stock purchase plan. Read SEC document |
| July 29, 2022 Filed Aug 2, 2022 17:33 UTC |
Surface Carol AEVP, Chief HR Officer
|
Disposition to issuerOrdinary Shares | 7,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020210 · form4.xml · nonDerivative · entry 1 Surface Carol A · CIK 0001485966 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,036 F1 · shares: Represents shares of performance-vesting restricted stock granted in July 2019 and earned dividend equivalent units that have been forfeited based on the Company's failure to meet the cumulative three year non-GAAP diluted earnings per share ("EPS") growth performance target. F2 · balance_after: This balance increased by 454 shares due to exempt transactions such as dividend reinvestment and employee stock purchase plan. Read SEC document |
| July 29, 2022 Filed Aug 2, 2022 21:53 UTC |
Wall Brett A.EVP & Pres Neuroscience
|
Disposition to issuerOrdinary Shares | 7,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020233 · form4.xml · nonDerivative · entry 1 Wall Brett A. · CIK 0001473812 · EVP & Pres Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,125 F1 · shares: Represents shares of performance-vesting restricted stock granted in July 2019 and earned dividend equivalent units that have been forfeited based on the Company's failure to meet the cumulative three year non-GAAP diluted earnings per share ("EPS") growth performance target. F2 · balance_after: This balance increased by 367 shares due to exempt acquisitions through dividend reinvestment. Read SEC document |
| July 29, 2022 Filed Aug 2, 2022 21:22 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
Disposition to issuerOrdinary Shares | 15,151 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020198 · form4.xml · nonDerivative · entry 1 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,218 F1 · shares: Represents shares of performance-vesting restricted stock granted in July 2019 and earned dividend equivalent units that have been forfeited based on the Company's failure to meet the cumulative three year non-GAAP diluted earnings per share ("EPS") growth performance target. F2 · balance_after: This balance increased by 423 shares due to exempt acquisitions through dividend reinvestment. Read SEC document |
| July 29, 2022 Filed Aug 2, 2022 21:18 UTC |
Martha GeoffreyDirector · Chairman and CEO
|
Disposition to issuerOrdinary Shares | 23,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020196 · form4.xml · nonDerivative · entry 1 Martha Geoffrey · CIK 0001560409 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,026 F1 · shares: Represents shares of performance-vesting restricted stock granted in July 2019 and earned dividend equivalent units that have been forfeited based on the Company's failure to meet the cumulative three year non-GAAP diluted earnings per share ("EPS") growth performance target. F2 · balance_after: This balance increased by 1,600 shares due to exempt acquisitions through dividend reinvestment. Read SEC document |
| July 29, 2022 Filed Aug 2, 2022 17:49 UTC |
TEN HOEDT ROBEVP & President EMEA
|
Disposition to issuerOrdinary Shares | 9,641 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020227 · form4.xml · nonDerivative · entry 1 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,177 F1 · shares: Represents shares of performance-vesting restricted stock granted in July 2019 and earned dividend equivalent units that have been forfeited based on the Company's failure to meet the cumulative three year non-GAAP diluted earnings per share ("EPS") growth performance target. F2 · balance_after: This balance increased by 400 shares due to exempt acquisitions through dividend reinvestment. Read SEC document |
| July 29, 2022 Filed Aug 2, 2022 21:38 UTC |
Salmon SeanEVP & President Cardiovascular
|
Disposition to issuerOrdinary Shares | 5,808 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020216 · form4.xml · nonDerivative · entry 1 Salmon Sean · CIK 0001792380 · EVP & President Cardiovascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,619 F1 · shares: Represents shares of performance-vesting restricted stock granted in July 2019 and earned dividend equivalent units that have been forfeited based on the Company's failure to meet the cumulative three year non-GAAP diluted earnings per share ("EPS") growth performance target. F2 · balance_after: This balance increased by 344 shares due to exempt acquisitions through dividend reinvestment. Read SEC document |
| May 03, 2022 Filed May 4, 2022 18:32 UTC |
OLEARY DENISE MDirector
|
Tax withholdingOrdinary Shares | 262 | $103.11 | $27,014.82 |
DisclosureSEC source: 0001127602-22-013323 · form4.xml · nonDerivative · entry 2 OLEARY DENISE M · CIK 0001145159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,917 F1 · balance_after: This balance increased by 737 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| May 03, 2022 Filed May 4, 2022 22:17 UTC |
Lofton Kevin EDirector
|
Tax withholdingOrdinary Shares | 161 | $103.11 | $16,600.71 |
DisclosureSEC source: 0001127602-22-013315 · form4.xml · nonDerivative · entry 2 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,374 F1 · balance_after: This balance increased by 18 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| May 03, 2022 Filed May 4, 2022 22:36 UTC |
Powell Kendall JDirector
|
Tax withholdingOrdinary Shares | 262 | $103.11 | $27,014.82 |
DisclosureSEC source: 0001127602-22-013326 · form4.xml · nonDerivative · entry 2 Powell Kendall J · CIK 0001298823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,417 F1 · balance_after: This balance increased by 516 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| May 03, 2022 Filed May 4, 2022 21:53 UTC |
DONNELLY SCOTT CDirector
|
Tax withholdingOrdinary Shares | 262 | $103.11 | $27,014.82 |
DisclosureSEC source: 0001127602-22-013284 · form4.xml · nonDerivative · entry 2 DONNELLY SCOTT C · CIK 0001233158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,862 F1 · balance_after: This balance increased by 78 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| May 03, 2022 Filed May 4, 2022 21:40 UTC |
ARNOLD CRAIGDirector
|
Tax withholdingOrdinary Shares | 262 | $103.11 | $27,014.82 |
DisclosureSEC source: 0001127602-22-013263 · form4.xml · nonDerivative · entry 2 ARNOLD CRAIG · CIK 0001188578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,419 F1 · balance_after: This balance increased by 30 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| May 03, 2022 Filed May 4, 2022 22:08 UTC |
HOGAN RANDALL JDirector
|
Tax withholdingOrdinary Shares | 262 | $103.11 | $27,014.82 |
DisclosureSEC source: 0001127602-22-013306 · form4.xml · nonDerivative · entry 2 HOGAN RANDALL J · CIK 0001189049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,147 F1 · balance_after: This balance increased by 30 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| May 03, 2022 Filed May 4, 2022 22:50 UTC |
ANDERSON RICHARD HDirector
|
Tax withholdingOrdinary Shares | 262 | $103.11 | $27,014.82 |
DisclosureSEC source: 0001127602-22-013328 · form4.xml · nonDerivative · entry 2 ANDERSON RICHARD H · CIK 0001200334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,182 F1 · balance_after: This balance increased by 373 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| May 03, 2022 Filed May 4, 2022 22:54 UTC |
Goldsmith Andrea JoDirector
|
Tax withholdingOrdinary Shares | 262 | $103.11 | $27,014.82 |
DisclosureSEC source: 0001127602-22-013330 · form4.xml · nonDerivative · entry 2 Goldsmith Andrea Jo · CIK 0001730514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,450 F1 · balance_after: This balance increased by 30 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| May 03, 2022 Filed May 4, 2022 22:23 UTC |
NABEL ELIZABETH GDirector
|
Tax withholdingOrdinary Shares | 262 | $103.11 | $27,014.82 |
DisclosureSEC source: 0001127602-22-013317 · form4.xml · nonDerivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,818 F1 · balance_after: This balance increased by 30 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| May 02, 2022 Filed May 4, 2022 18:32 UTC |
OLEARY DENISE MDirector
|
GrantOrdinary Shares | 1,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013323 · form4.xml · nonDerivative · entry 1 OLEARY DENISE M · CIK 0001145159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,179 Read SEC document |
| May 02, 2022 Filed May 4, 2022 22:17 UTC |
Lofton Kevin EDirector
|
GrantOrdinary Shares | 1,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013315 · form4.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,535 Read SEC document |
| May 02, 2022 Filed May 4, 2022 22:36 UTC |
Powell Kendall JDirector
|
GrantOrdinary Shares | 1,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013326 · form4.xml · nonDerivative · entry 1 Powell Kendall J · CIK 0001298823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,679 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.